Cefapirin


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : IV/IM 0.5-1 g 4-6 hrly. Up to 12 g/day in severe infections.
Dosage Details
Parenteral
Susceptible infections
Adult: 0.5-1 g every 4-6 hr IM or IV; up to 12 g daily in severe infections.
Renal Impairment
CrClDosage
<51 g every 24 hr.
5-201 g every 12 hr.
Contraindications
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status.
Adverse Reactions
Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; pseudomembranous colitis; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Drug Interactions
Nephrotoxic drugs such as aminoglycosides may increase risk of kidney damage. Enhanced nephrotoxicity with a loop diuretic. Renal excretion inhibited by probenecid. Bacteriostatic antibacterials.
Lab Interference
Positive direct antiglobulin Coombs' test; falsely high values with Jaffe method of measuring creatinine concentrations; +ve reactions for false glucose using copper-reduction reactions; transient increases in liver enzyme values.
Action
Description: Cefapirin inhibits final cross-linking stage of peptidoglycan production thus inhibiting bacterial cell wall synthesis. It is most active against gm+ve cocci and has moderate activity against some gm-ve bacilli.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefapirin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in